Making the Most of *In Vitro* Tests to Diagnose Food Allergy

Alexandra F. Santos, MD, PhD,*a,b* and Helen A. Brough, MBBS, PhD* a,b* London, United Kingdom

**Information for Category 1 CME Credit**
Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.

**Method of Physician Participation in Learning Process:** The core material for these activities can be read in this issue of the Journal or online at the JACI: *In Practice* Web site: www.jaci-inpractice.org/. The accompanying tests may only be submitted online at www.jaci-inpractice.org/. Fax or other copies will not be accepted.

**Date of Original Release:** March 1, 2017. Credit may be obtained for these courses until February 28, 2018.

**Copyright Statement:** Copyright © 2017-2019. All rights reserved.

**Overall Purpose/Goal:** To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.

**Target Audience:** Physicians and researchers within the field of allergic disease.

**Accreditation/Provider Statements and Credit Designation:** The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**List of Design Committee Members:** Alexandra F. Santos, MD, PhD, and Helen A. Brough, MBBS, PhD

**Learning Objectives:**
1. To describe the different *in vitro* tests for diagnosing food allergy and their diagnostic performance.
2. To analyze the results of allergy tests to determine the likelihood of clinical allergy.
3. To explain the factors that influence the decision to perform an oral food challenge.

**Recognition of Commercial Support:** This CME has not received external commercial support.

**Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations:** A. F. Santos has received research support from the Medical Research Council (MRC Clinical Research Training Fellowship G0902018, MRC Centenary Early Career Award, MRC Clinician Scientist Fellowship MR/M008517/1), Immune Tolerance Network and National Institutes of Health, and the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust; has received lecture fees from Thermo Scientific, Nutricia and Infomed; has received travel support from European Academy of Allergy and Clinical Immunology (EAACI), British Society of Allergy and Clinical Immunology (BSACI), Academy of Medical Sciences, Portuguese Society of Allergy and Clinical Immunology (SPAIC), Spanish Society of Allergy and Clinical Immunology (SEAIC), and French Meeting of Molecular Allergology. H. A. Brough has received consultancy fees from MEAD Johnson Nutrition and Nutricia; has received research support from the Food Allergy Research and Education Charity grant, Immune Tolerance Network, and National Institutes of Health; has received lecture fees from MEDA Pharmaceuticals, Thermo Scientific, and Nutricia; receives royalties from Wiley Blackwell Ltd; has received travel support from British Society of Allergy and Clinical Immunology, MEDA Pharmaceuticals, Thermo Scientific, and Nutricia; and has received research support from Thermo Scientific, Stallergenes, and Meridien Foods.

*Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King’s College London, London, United Kingdom

*Children’s Allergy Service, Guy’s and St Thomas’ Hospital, London, United Kingdom

This work was funded by the Medical Research Council through MRC Clinician Scientist Fellowship MR/M008517/1 awarded to A.F.S.

Conflicts of interest: A. F. Santos has received research support from the Medical Research Council (MRC Clinical Research Training Fellowship G0902018, MRC Centenary Early Career Award, MRC Clinician Scientist Fellowship MR/M008517/1), Immune Tolerance Network and National Institutes of Health, and the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust; has received lecture fees from Thermo Scientific, Nutricia and Infomed; has received travel support from European Academy of Allergy and Clinical Immunology (EAACI), British Society of Allergy and Clinical Immunology (BSACI), Academy of Medical Sciences, Portuguese Society of Allergy and Clinical Immunology (SPAIC), Spanish Society of Allergy and Clinical Immunology (SEAIC), and French Meeting of Molecular Allergology. H. A. Brough has received consultancy fees from MEAD Johnson Nutrition and Nutricia; has received research support from the Food Allergy Research and Education Charity grant, Immune Tolerance Network, and National Institutes of Health; has received lecture fees from MEDA Pharmaceuticals, Thermo Scientific, and Nutricia; receives royalties from Wiley Blackwell Ltd; has received travel support from British Society of Allergy and Clinical Immunology, MEDA Pharmaceuticals, Thermo Scientific, and Nutricia; and has received research support from Thermo Scientific, Stallergenes, and Meridien Foods.

Received for publication October 3, 2016; revised December 5, 2016; accepted for publication December 19, 2016.

Corresponding author: Alexandra F. Santos, MD, PhD, Department of Paediatric Allergy, King’s College London, 2nd floor, South Wing, St. Thomas’ Hospital, London SE1 7EH, United Kingdom. E-mail: alexandra.santos@kcl.ac.uk.

© 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

http://dx.doi.org/10.1016/j.jaip.2016.12.003
Various *in vitro* tests assess different aspects of the underlying immune mechanism of IgE-mediated food allergy. Some can be used for diagnostic purposes; specific IgE to allergen extracts is widely available; specific IgE to allergen components is used in most specialist centers, and the basophil activation test is becoming increasingly used clinically. IgE to allergen peptides, T-cell assays, allergen-specific/total IgE ratios, and allergen-specific IgG4/IgE ratios are currently reserved for research. Different factors can modulate the likelihood of IgE-mediated food allergy of a given allergy test result, namely, the patients’ age, ethnicity, previous allergic reaction to the identified food, comorbid atopic conditions, and geographical location, and need to be taken into account when interpreting the allergy test results in the clinic. The importance of the specific food, the clinical resources available, and patient preferences are additional aspects that need to be considered when deciding whether an oral food challenge is required to reach an accurate diagnosis of IgE-mediated food allergy. © 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). (J Allergy Clin Immunol Pract 2017;5:237-48)

**Key words:** In vitro tests; Diagnosis; Food allergy; Specific IgE; Basophil activation test; Component-resolved diagnosis; IgG4/IgE ratio; Specific/total IgE ratio; Peptide microarray; T-cell assay

Food allergy (FA) is an adverse reaction caused by an abnormal response of the immune system to food allergens. Food allergies are classified based on the involvement of IgE antibodies in their pathogenesis. This review will focus on IgE-mediated FA. The immunologic mechanism underlying IgE-mediated allergy is type I hypersensitivity. During allergic sensitization, food allergens are presented to T cells, a Th2-skewed immune response commits B cells to IgE production and allergen-specific IgE binds to the high-affinity IgE receptors (FcεR1) on the surface of mast cells and basophils. In allergic individuals, on subsequent exposure to the allergenic food, multivalent allergens cross-link receptor-bound IgE leading to mast cell and basophil activation and the release of preformed mediators and *de novo* synthesis of leukotrienes and cytokines, which contribute to the symptoms that patients experience during allergic reactions.

Various *in vitro* assays reflect different aspects of the immunologic mechanisms of IgE-mediated FA. For instance, the amount of circulating allergen-specific IgE antibodies can be determined using immunoenzymatic assays, and basophil activation and T-cell proliferation in response to allergen can be assessed using flow cytometry (Figure 1). Some of these *in vitro* assays can be used to diagnose FA and/or defer or obviate the need for an oral food challenge (OFC). An OFC is the most accurate test to diagnose FA but requires expensive resources, highly trained personnel, and carries the risk of causing an acute allergic reaction. Therefore, in clinical practice, the diagnosis of FA is based on a combination of the clinical history and the results of allergy tests when possible. The clinical history, including the allergic reaction(s) to the culprit food and the dietary history, is the cornerstone of the diagnosis of FA; it guides the selection of allergens to be tested and the interpretation of allergy test results. In this review, we discuss the main

**In Vitro Tests for IgE-Mediated Food Allergy**

Specific IgE to allergen extracts

Specific IgE (sIgE) testing has been used to diagnose FA for many years. Automated systems permit the use of enzymatic immunoassays for a large number of samples in a standardized way; however, levels determined with different methodology may not be comparable. IgE is quantified using kilounits per liter (kU/L) based on the World Health Organization Reference Standard with 1 unit equaling 2.42 ng of IgE.

Using the cutoff of 0.35 kU/L, sIgE testing has high sensitivity but poor specificity to diagnose FA. For example, in the case of peanut allergy (PA), sIgE to peanut has a sensitivity of 75% to 100% and a specificity of 17% to 63%.[6-13] Adopting 95% positive predictive value (PPV) cutoffs, the specificity of IgE testing increases. Following on with the example of PA, the cutoff of 15 kU/L showed a specificity of 96.8% and a sensitivity of only 28.4% in a UK study.[2] This indicates that the 95% PPV cutoffs can be useful to confirm the diagnosis of FA, especially if there is a recent history of an immediate-type allergic reaction. On the contrary, the cutoff of 0.35 kU/L can be useful to exclude the diagnosis of FA as it has a high negative predictive value (NPV). Levels of sIgE between positive and negative cutoffs without a clear clinical history do not allow us to confirm or exclude the diagnosis, falling in the so-called immunological gray area.[15-19] Positive and negative cutoffs can be helpful in guiding the clinical diagnosis of FA; however, they are not absolute and need to be interpreted in light of the clinical history, as patients can still be allergic or tolerant below and above 95% NPV and 95% PPV, respectively. PPV and NPV decision levels have been identified for sIgE to other foods (Table 1).

Diagnostic cutoff values can vary widely in different studies. For instance, the 95% PPV cutoff to diagnose PA was 15 kU/L in US[14] and UK[1] studies, but was 24.1 kU/L, 34 kU/L, and 57 kU/L in studies performed in the Netherlands,[17] Australia,[18] and France,[19] respectively. These differences can result from the patient population (eg, prevalence of FA, comorbidities) and/or from the research study where the cutoffs were determined (eg, inclusion criteria, reference standard against which the performance of sIgE was compared, criteria for referring for OFC and the OFC protocol).[20] These factors need to be taken into account when comparing studies and when extrapolating cutoffs from published studies into daily clinical practice. When critically reviewing the literature for diagnostic decision levels for FA one should take into consideration the limitations of studies assessing the diagnostic utility of allergy tests (eg, small sample size, selected sample of participants, OFC not done in all participants, etc.).[21] Validated diagnostic cutoffs are reliable when applied to a similar population to the population in which they were generated. PPVs are a function of the sensitivity and specificity of the test and the prevalence of the disease; therefore, they are only valid for patients who have the same pretest probability of disease as the population in which the PPV was established. For instance, in our clinic population in London, the cutoff of 15 kU/L for peanut sIgE had 95% PPV in 2 different studies performed approximately 10 years apart.[2,16] The
consistency of these findings indicates that the identified cutoff can be reliably applied to our patient population in the clinic.

**Specific IgE to allergen components**

Conventional IgE testing uses natural extracts containing a complex mixture of proteins. Allergen sIgE to component allergen tests for IgE binding to single allergens, allowing more precise profiling of the allergen-sIgE repertoire. The list of allergenic molecules available for testing is not complete; thus IgE assays using extracts are likely to be useful for some time. sIgE testing to components is available for single allergens and for multiple allergens in microarrays. Multiplex assays may introduce concerns where they reveal sensitization to molecules with potentially no clinical relevance as they are all tested independent of the patient’s history. However, multiplex assays can be useful in identifying patterns of sensitization in complex polysensitized patients (eg, patients sensitized to pollen, plant foods, and latex). Precise protein identity is essential when interpreting multiplex testing.25

The food that has received the most research into component allergens and their validation in terms of clinical relevance is peanut. The number of identified peanut allergens is extensive although not all of these are available for testing in clinical practice (Table II). The immunodominant peanut allergen in adults and children is Ara h 2 based on OFC, serial skin prick test (SPT) dilutions, and basophil degranulation assays.24-27 Secondary sensitization to peanut occurs because of panallergens such as nonspecific lipid-transfer proteins (nSLTPs) (eg, Pru p 3 in peach giving rise to Ara h 9 sIgE), Bet v 1 homologs (eg, Bet v 1 in birch pollen giving rise to Ara h 5 sIgE), and profilins (eg, Phi p 12 in grass pollen or Bet v 2 in birch pollen giving rise to Ara h 5 sIgE). Similar to what has been reported for peanut sIgE, diagnostic cutoffs for Ara h 2 sIgE vary between studies (Table III).

Of the tree nuts, hazelnut has received the most extensive evaluation leading to the identification of seed storage proteins (eg, Cor a 9 and Cor a 14) as well as cross-reactive proteins (eg, Cor a 8 and Cor a 1) as allergens. sIgE to whole hazelnut has a poor predictive value for clinical reactivity due to cross-reactivity with birch pollen. Birch pollen-associated hazelnut allergy is the dominant phenotype, although Cor a 9 and 14 are the allergens more commonly associated with systemic reactions (Table III).27-30 In Danish28, German,29 and Belgian children, Cor a 14 was superior to Cor a 9 in predicting challenge-proven hazelnut allergy; however, in Dutch children Cor a 9 was the best predictor.26 It was postulated that these differences were due to the age of children assessed with Cor a 9 specificity decreasing with age and Cor a 1 specificity increasing with age.28,31 Other 2S albumins have been identified for walnut (Jug r 1),34,35 cashew (Ana o 3),36 and Brazil nut (Ber e 1)37 (Table III).

Casein (Bos d 8), beta-lactoglobulin (Bos d 5), and alpha-lactoglobulin (Bos d 4) are the major allergens in cow’s milk. Sensitivity to various cow’s milk proteins is widely distributed; thus generally no single allergen is considered to be immunodominant.38 In some studies, Bos d 8 was the best predictor of challenge-proven cow’s milk allergy (CMA).39,40 In a Spanish study, the optimum cutoffs for Bos d 8 increased with age; using 2 kU/L (13-18 months), 4.2 kU/L (19-24 months), and 9 kU/L (24-36 months) gave a sensitivity of 95% and a specificity of 90%.41 This observation is important with regard to cutoffs for transient food allergies, such as cow’s milk and egg, as one would expect that children who persist with CMA beyond 2 years would have higher casein levels than those who have already grown out of their CMA. In fact, IgE antibodies directed against sequential casein epitopes are a marker of persistent CMA.42 High casein-IgE antibodies are predictive of baked CMA as casein is more resistant
to extensive heating. Clinical decision points for a positive challenge to baked milk have been reported (Table III). The main hen’s egg allergens are ovomucoid (Gal d 1), ovalbumin (Gal d 2), conalbumin (Gal d 3), and lysozyme (Gal d 4). Ovomucoid is considered to be the immunodominant allergen based on OFCs to heated and ovomucoid-depleted egg and serial dilutions of ovomucoid SPT and ovomucoid sIgE in egg allergic children. Ovomucoid is stable against heat and digestion by proteinases; this is why it has been evaluated in the prediction of tolerating extensively heated egg (Table IV). IgE antibodies to sequential epitopes of ovomucoid have been shown to predict persistent egg allergy beyond the age of 11 years.

Component-resolved diagnosis (CRD) of wheat allergy has gained interest as wheat extract IgE testing has a poor predictive value. The major wheat allergens relevant for FA (rather than Baker’s asthma) are glutens that can be subdivided into gliadins (subunits α, β, γ, and τ) and glutenins (high molecular and low molecular weight). The role of omega-5-gliadin (Tri a 19) in wheat-dependent exercise-induced anaphylaxis has been shown in several studies; however, results for this component in the prediction of IgE-mediated wheat allergy are conflicting. In a Japanese population, Tri a 19 has been shown to correctly predict challenge-proven IgE-mediated allergy to wheat, and in a Swedish population, Tri a 19 correlated better with OFC-proven IgE-mediated wheat allergy than the extract-based in vitro test or other component allergens. However, the results for Tri a 19 have not been reproduced in American or German populations.

Allergens predictive of systemic reactions to soya include the seed storage proteins Gly m 5, 6, and 8. Gly m 5 and 6 predicted systemic allergic reactions to soya (with both positive Gly m 5 and 6 giving an odds ratio of 12 for severe reactions) more than the Bet v 1 homolog Gly m 4. More recently, the 2S albumin Gly m 8 was found to be a better marker for systemic reactions to soya than Gly m 5 and 6 (or soy extract), but it still misclassified many patients. It is important to note that sole reactivity to the PR-10 protein Gly m 4 has been responsible for anaphylaxis after consumption of unprocessed soya.

**Ratios: allergen-specific/total IgE and allergen-specific IgG4/IgE**

To try to improve the diagnostic performance of food sIgE, the added value of total IgE and food-specific IgG4 has been tested in food-specific/total IgE ratios or food-specific IgG4/ IgE ratios. Some studies showed an improvement in the prediction of OFC outcome with specific/total IgE ratios compared with sIgE alone, although other studies did not find it to be useful. The discrepancy in these findings could be due to the foods studied, as Gupta et al. found the specific/total IgE ratio particularly useful for persistent food allergies (eg, peanut, tree nuts, shellfish, and seeds) and the study by Mehl et al focused on transient food allergies, namely, cow’s milk, egg, and wheat allergies. Recently, in a multicenter study of children with suspected peanut or hazelnut allergies, calculating the Ara h 2/peanut sIgE or Ara h 2-specific/total IgE ratios did not improve the diagnostic performance of Ara h 2 sIgE. Peanut-specific/total IgE was also not better than Ara h 2 sIgE in diagnosing PA. Similar results were reported for the relative diagnostic performance of Cor a 14/hazelnut sIgE, Cor a 14-specific/total IgE, and Cor a 14 sIgE and hazelnut-specific/total IgE to diagnose hazelnut allergy.

Food-specific IgG4/IgE ratios have been determined in various studies, but their diagnostic utility has not been established. Sensitized-tolerant children tend to have higher allergen-specific IgG4/IgE ratios than allergic children. For instance, peanut-sensitized tolerant patients have a higher peanut-specific as well as Ara h 1-, Ara h 2-, and Ara h 3-specific IgG4/IgE ratios compared with peanut-allergic. This increased IgG4 in relation to IgE was not due to higher peanut consumption as the majority of children had not knowingly eaten peanut before entering the study. A higher peanut-specific IgG4/IgE ratio has also been observed in peanut allergic patients treated with peanut oral immunotherapy and in high-risk infants who consumed peanut early in life and developed tolerance. Conversely, allergic patients tend to show a higher food sIgE/IgG4 ratio. For example, egg allergic patients who react to baked egg have higher ovalbumin and ovomucoid sIgE/IgG4 ratios than egg allergic patients who tolerate baked egg.

**Basophil activation test**

The basophil activation test (BAT) is a functional assay that uses live basophils in whole blood to detect the ability of IgE to mediate activation of basophils after stimulation with allergen. It goes beyond the detection of IgE binding to allergen to test IgE function, which depends not only on the allergen-sIgE levels but also on IgE epitope specificity, affinity, and clonality. The basophils of allergic patients typically show a dose-dependent expression of activation markers, such as CD63 or CD203c, whereas the basophils of sensitized-tolerant patients do not express or have a much lower expression of activation markers after stimulation with allergen. In a PA study, basophils of peanut allergic patients showed higher basophil activation to peanut compared with peanut-sensitized-tolerant even in the subgroup where allergic and tolerant children had comparable levels of peanut sIgE. The difference in upregulation of basophil activation markers in response to allergen between allergic and nonallergic patients forms the basis of the use of the BAT to diagnose FA.
TABLE III. Allergen components associated with clinical allergy and examples of cutoffs for specific IgE testing to main allergen components

| Foods          | Components associated with clinical allergy | Cutoffs for specific IgE to main components |
|----------------|--------------------------------------------|--------------------------------------------|
| Peanut         | Ara h 1                                    | Ara h 2 sIgE: 0.35 to 42.2 kU/L had 90%-95% PPV, Ara h 3 sIgE: 0.35 to 42.2 kU/L had 90%-95% PPV, Ara h 9 (in Southern Europe) sIgE: 0.35 to 42.2 kU/L had 90%-95% PPV |
| Hazelnut       | Cor a 9                                    | Cor a 9 sIgE: 1 kU/L had 83% accuracy, Cor a 14 sIgE: 0.72 to 47.8 kU/L had 87%-90% accuracy |
| Cashew, Pistachio | Ana o 3                                    | Ana o 3 sIgE: 0.16 kU/L had 97.1% accuracy for cashew and/or pistachio nut allergy, Ana o 8 (in Southern Europe) sIgE: 0.1 kU/L had 83% NPV |
| Brazil nut     | Ber e 1                                    | Ber e 1 sIgE: 0.25 kU/L had 94% PPV |
| Walnut         | Jug r 1                                    | Jug r 1 sIgE: 0.1 kU/L had 91% PPV |
| Soya           | Gly m 5                                    | Gly m 8 sIgE: 1 kU/L had 89% PPV, Gly m 8 sIgE: 0.1 kU/L had 83% NPV |
| Wheat          | Tri a 19 (IgE-mediated wheat allergy and WDEIA) | Tri a 19 sIgE: 0.04 AU had 100% PPV and 88% NPV for IgE-mediated wheat allergy, Tri a 14 (nsLTP involved in Baker’s asthma) sIgE: 0.1 kU/L had 83% NPV |
| Cow’s milk     | Casein (for baked milk allergy and persistent cow’s milk allergy) | Casein sIgE: 10 kU/L had 95% PPV for a positive OFC to baked milk, Casein sIgE: 5 kU/L had 50% PPV for a positive OFC to baked milk |
| Egg            | Ovomucoid (for cooked or baked egg allergy and persistent egg allergy) | Ovomucoid sIgE: 3.74-26.6 kU/L had 95% PPV for cooked egg allergy, Ovomucoid sIgE: 50 kU/L had 90% PPV and Ovomucoid sIgE: 0.35 kU/L had 90% NPV for a positive OFC to baked egg |

nsLTP, Non-specific lipid-transfer protein; OFC, oral food challenge; WDEIA, wheat-dependent exercise-induced anaphylaxis.

The main added value of the BAT in the diagnosis of FA compared with tests routinely used in clinical practice, such as SPT and sIgE to allergen extracts, is its enhanced specificity with often preserved sensitivity. For instance, the BAT to peanut showed 98% sensitivity and 96% specificity to diagnose PA, with the specificity reaching 100% in a subsequent validation. The specificity of the BAT ranged between 77% and 100% in other studies (Table IV). The BAT with single allergen components can potentially improve its diagnostic accuracy, but further research studies are needed. The BAT has been shown to be potentially useful in identifying the culprit allergen in cases of pollen-food allergy syndrome (PFAS), allergy to red meat, and food-dependent exercise-induced anaphylaxis. As for other diagnostic tests, cutoffs determined for the BAT can vary with the patient population, the design of the study, and the methodology adopted for the BAT procedure and data analyses.

The BAT requires fresh blood and uses flow cytometry for which appropriate equipment and trained personnel are needed. It is anticipated that the BAT is reserved for selected cases where the results of routinely used tests do not allow a precise diagnosis. Indeed, in the previously mentioned study, the BAT sustained its good performance in a subgroup of patients with equivocal test results for SPT, peanut sIgE, and Ara h 2 sIgE with 92% accuracy compared with its 97% accuracy in the study population overall. Used as a second step in the diagnostic workup, the BAT was performed in patients who would have otherwise been referred for an OFC after standard allergy testing. A positive BAT confirmed the diagnosis of FA and dispensed with an OFC, whereas patients with a negative BAT or nonresponder basophils (ie, basophils that solely responded to non-IgE-mediated and not to IgE-mediated stimulants) needed to be referred for the OFC. This stepwise approach ensured a 67% reduction in the need for the OFC.

As any other diagnostic test, the BAT cannot be used in isolation to diagnose FA. The results of the BAT need to be considered in light of the clinical history. In addition to patients with a negative BAT or nonresponder basophils, patients with BAT results that are discordant with the clinical history require an OFC to confirm or refute the diagnosis of FA.

IgE to allergen peptides

IgE specificity can be refined further by determining the allergen epitopes to which IgE binds. This has been evaluated using short linear allergen peptides of 15 to 20 amino acids bound to a solid phase (eg, microarray or spot membrane) using immunofluorescence. Beyer et al identified 5 immunodominant epitopes in selected peanut allergen peptides in 2003. Later, a microarray containing peptides of the major peanut allergens, Ara h 1, Ara h 2, and Ara h 3, identified epitopes bound more by the IgE of peanut allergic patients than by the IgE of peanut sensitized-tolerant patients; this allowed the development of a machine-learning method that markedly enhanced the diagnostic utility of the microarray.

Similar methods have tested the utility of IgE to allergen peptides in diagnosing and in predicting the resolution of other
### TABLE IV. Basophil activation test to food extracts or to component allergens in the diagnosis of food allergy

| Food extract or allergen component | Cutoffs | Diagnostic performance |
|----------------------------------|---------|------------------------|
|                                  | S       | Sp                     | PPV | NPV | LR⁺ | LR⁻  |
| Cow’s milk                       | SI CD203c ≥ 1.9<sup>17</sup> to diagnose resolution of CMA | 89% | 83% | 86% | 86% | 5.24 | 0.13 |
|                                  | >6% CD63+<sup>117</sup> | 91% | 90% | 81% | 96% | 9.10 | 0.10 |
| Casein                           | SI CD203c ≥ 1.3<sup>27</sup> | 67% | 71% | 74% | 63% | 2.31 | 0.46 |
| Egg white                        | SI CD203c ≥ 2.4<sup>17</sup> to diagnose baked egg allergy | 74% | 62% | 85% | 44% | 1.95 | 0.42 |
|                                  | SI CD203c ≥ 1.7<sup>27</sup> to diagnose raw egg allergy | 77% | 63% | 92% | 33% | 2.08 | 0.37 |
| Ovalbumin                        | ≥5% CD63+ or SI CD203c ≥ 1.6 to diagnose egg allergy | 77% for CD63 | 100% for CD63 | Inf⁠† | 0.23 for CD63 |
|                                  | 63% for CD203c | 96% for CD203c | 15.75 for CD203c | 0.39 for CD203c |
| Ovomucoid                        | SI CD203c ≥ 1.7<sup>27</sup> to diagnose baked egg allergy | 80% | 73% | 90% | 53% | 2.96 | 0.27 |
|                                  | SI CD203c ≥ 1.6<sup>27</sup> to diagnose raw egg allergy | 83% | 83% | 97% | 42% | 4.88 | 0.20 |
| Wheat                            | >11.1% CD203c+ to diagnose wheat allergy<sup>88</sup> | 86% | 58% | 77% | 71% | 2.05 | 0.24 |
| Omega-5 gliadin                  | rTri a 19; >14.4% CD203c+ to diagnose wheat allergy<sup>68</sup> | 86% | 58% | 77% | 71% | 2.05 | 0.24 |
| Peanut                           | ≥4.78% CD63+<sup>16</sup> to diagnose peanut allergy<sup>88</sup> | 83% | 63% | 81% | 67% | 2.24 | 0.27 |
| Ara h 1                          | ND | BAT to Ara h 1 was higher in peanut allergic patients compared with controls from Southern Spain<sup>74</sup> |
| Ara h 2                          | 92% | 77% | 98% | 98% | 24.50 | 0.02 |
| Ara h 3                          | ND | There was no difference in BAT to Ara h 3 between peanut allergic and control subjects from Southern Spain<sup>74</sup> |
| Ara h 6                          | ND | There was no difference in BAT to Ara h 6 between peanut allergic and control subjects from Southern Spain<sup>74</sup> |
| Ara h 8                          | ND | There was no difference between CD-sens to Ara h 8 between patients with PFAS to peanut and patients with sIgE to Ara h 8 and no reaction during OFC to roasted peanuts<sup>69</sup> |
| Ara h 9                          | ND | BAT to Ara h 9 was higher in peanut allergic patients compared with controls from Southern Spain<sup>74</sup> |
| Hazelnut                         | CD-sens > 1.7<sup>60</sup> to diagnose hazelnut allergy | 100% | 97% | 33.33 | 0.00 |
|                                  | ≥6.7% CD63+<sup>70</sup> to diagnose PFAS to hazelnut | 85% | 80% | 4.25 | 0.19 |
| Peach                            | ≥20% CD63+ and SI CD63 ≥ 2<sup>72</sup> | 87% | 69% | 2.81 | 0.19 |
| Pru p 3                          | ≥20% CD63+ and SI CD63 ≥ 2<sup>72</sup> | 77% | 97% | 25.67 | 0.24 |
| Apple                            | ≥17% CD63+<sup>71</sup> to diagnose PFAS to apple | 88% | 75% | 3.52 | 0.16 |
| Carrot                           | ≥8.9% CD63+<sup>70</sup> to diagnose PFAS to carrot | 85% | 85% | 5.67 | 0.18 |
| Celery                           | ≥6.3% CD63+<sup>70</sup> to diagnose PFAS to celery | 85% | 80% | 4.25 | 0.19 |

**BAT**: Basophil activation test; **CMA**: cow’s milk allergy; **Inf**: infinity; **LR⁺**: positive likelihood ratio; **LR⁻**: negative likelihood ratio; **ND**: not determined; **NPV**: negative predictive value; **OFC**: oral food challenge; **PFAS**: pollen-food syndrome; **PPV**: positive predictive value; **S**: sensitivity; **SI**: stimulation index; **Sp**: specificity.

*Likelihood ratios were calculated from sensitivity and specificity using the formulas LR⁺ = sensitivity/(1 − specificity) and LR⁻ = (1 − sensitivity)/specificity.

†Infinity, the denominator is zero.
TABLE V. Factors modulating the interpretation of allergy test results

| Factors identified in the clinical history | Effect on the probability of clinical allergy for a given specific IgE level |
|-------------------------------------------|---------------------------------------------------------------------------|
| Reported immediate allergic reaction to the specific food | A history of reacting to the tested food supports the clinical relevance of detected IgE. |
| (Younger) Age | Lower levels of allergen-specific IgE have increased clinical relevance in young children. |
| (Black) Ethnicity | Black race is associated with higher levels of allergen-specific IgE with decreased clinical relevance. |
| Atopic eczema | Polyclonal IgE response can be non-allergen-specific and thus decrease clinical relevance of a given specific IgE level. |
| Concomitant inhalant allergies | Pollen sensitization can cause false-positive results of specific IgE to plant food extracts. |
| Atopic population | Positive predictive value of a given specific IgE level increases with the increase in the prevalence of the disease in the population. |
| Geographical location | Variable | Clinical relevance of IgE to extracts and patterns of sensitization to allergen components can vary with inhalant allergen exposure typical of certain geographical locations. |

These factors affect the pretest probability and therefore influence the resulting post-test probability.

food allergies. In a CMA study, IgE binding was more diverse and had higher affinity for cow’s milk allergen peptides in milk allergic patients reacting to baked milk compared with patients who reacted to unheated milk but tolerated baked milk, suggesting that the peptide microarray could be useful in identifying different phenotypes of CMA.

**T-cell assays**

T-cell responses are central to the development of oral tolerance in nonallergic individuals and to the development of the allergic immune response in allergic individuals. Peanut allergic individuals have been shown to have greater proliferation of their T cells when their PBMCs were stimulated with whole peanut or individual major peanut allergens. Peanut allergic patients also showed a typical Th2-skewed response to peanut allergen with higher levels of IL-4, IL-5, and IL-13, whereas nonallergic controls showed a Th1-type response characterized by IFN-gamma production. Interestingly, peanut allergic and peanut-sensitized-tolerant individuals showed higher T-cell proliferation compared with nonsensitized controls; however, only allergic patients showed a Th2-skewed response to peanut allergens. These findings suggest that the absence of clinical reactivity in sensitized individuals is an active ongoing process, whereas in nonsensitized individuals, it is a passive process, probably due to anergy or clonal deletion.

Food allergic patients may also have impaired regulatory T-cell function in response to specific food allergens. Dang et al recently showed that egg and/or peanut allergic infants had a reduction in the number of T regulatory cells and a lower ratio of activated regulatory/effector T cells in vitro after in vivo allergen exposure during the OFC. This is consistent with studies in mouse models.

**CLINICAL REASONING TO DIAGNOSE FOOD ALLERGY**

The tests available for routine use in the clinic can vary, with some practices using mainly SPT, others mainly sIgE, and others both. sIgE to allergen components is used in most specialist centers and the BAT is becoming increasingly used clinically. The other tests described in the previous section are reserved for use in the research setting, namely, peptide microarrays and T-cell assays.

**Interpretation of allergy test results**

The ultimate goal of the allergy test result is to determine the probability of clinical allergy; this is then used to decide whether an OFC is warranted. The probability of clinical allergy depends first and foremost on the clinical history (Table V) and secondarily on the allergy test result (Tables I, III, and IV). For example, if a patient consumes age-appropriate amounts of the food regularly without developing any symptoms, the probability of having FA is negligible regardless of the allergy test results; such patients should in fact not be tested as a false-positive result could be confusing for the patient and lead to unnecessary food avoidance. The clinical history provides information that enable the clinician to establish a pretest probability of FA that will be used in the research setting, namely, peptide microarrays and T-cell assays.

These factors affect the pretest probability and therefore influence the resulting post-test probability.
TABLE VI. Factors influencing the decision to perform an oral food challenge (OFC)

| Factors | Effect on the decision to perform an OFC |
|---------|-----------------------------------------|
| History of an allergic reaction | A previous history of a reaction to the specific food increases the chance of reacting during the OFC. |
| Recent exposure to the food | A recent allergic reaction or the consumption of age-appropriate amount of the food precludes the OFC. |
| (Low) specific IgE levels | Current low level of food-specific IgE and >50% decline within the last year indicate lower likelihood of a positive OFC. |
| Importance of the food | The importance of the food to the child’s diet and social life and her or his willingness to eat the food regularly in the case of a negative challenge favor performing an OFC. |
| Resources available | The resources available may limit the number of OFCs offered to patients. |
| Patient preferences | Variable | Patient may wish to undergo an OFC or not and her or his preferences need to be taken into account. |

The decision to perform an OFC is made when the probability of a systemic reaction is sufficient for there to be concern and low enough that the OFC is likely to be passed. The arrows indicate the effect on the decision to perform an OFC: the arrow pointing up means weighing pro and the arrow pointing down means weighing con performing an OFC.

Geographical location is another factor that may influence the clinical relevance of a given sIgE level. A study by Vereda et al. illustrates this nicely for PA. In Northern and Central Europe, sensitization to birch pollen leads to high prevalence of sensitization to Ara h 8, the Bet v 1-homolog, which typically causes oral allergic symptoms. In Spain, exposure to birch pollen and sensitization to Ara h 8 are rare and peanut allergic patients are often sensitized to Ara h 9 (nsLTP), probably as a consequence of primary sensitization to peach LTP. In the United States and in the United Kingdom, the most common pattern of sensitization in peanut allergic patients is the combination of IgE to Ara h 1, Ara h 2, and Ara h 3, although other patterns may be found in individual patients.

Finally, the clinical setting influences the predictive value of sIgE levels, with increasing likelihood of clinical allergy going from the general population to secondary care and then to specialist centers. In studies performed in the general population, the prevalence of sensitization to foods such as cow’s milk and egg was much lower than in a population recruited from specialist centers. For example, approximately 8% and 3%-4% of children in National Health and Nutrition Examination Survey 2005-2006 and 78% and 89% of children in Consortium of Food Allergy Research (COFAR) were sensitized to cow’s milk and egg, respectively, although this is probably an extreme example as a positive SPT to cow’s milk and/or egg was one of the inclusion criteria in COFAR, and therefore it is a highly selected population.

Factors influencing the decision of performing an oral food challenge

The main reason to perform an OFC is to identify the food that caused the allergic reaction for the initial diagnosis and for monitoring resolution of FA. Other reasons for an OFC include assessing the status of tolerance to cross-reactive foods (eg, tree nuts in PA or peanut in egg allergy) and expanding the diet in foods not yet introduced but with positive allergy tests. This

concomitant atopic diseases, geographical location, and the clinical setting. This is best studied for sIgE testing.

The clinical relevance of a given allergen sIgE result can vary depending on the age of the patient, with lower levels of sIgE having increased clinical relevance in younger patients. Ninety-five percentage PPV cutoffs have been established for children <2 years at lower levels of food sIgE compared with cutoffs for older children.

Diagnostic decision levels may be affected by the patients’ ethnicity. Black race is associated with a higher prevalence of sensitization to foods and a higher level of total IgE compared with Caucasians despite lower prevalence of FA. This discrepancy suggests that patients of black ethnicity may have more clinically irrelevant IgE and therefore higher diagnostic cutoffs. Indeed, the 95% cutoffs defined in the United Kingdom for peanut sIgE and Ara h 2 sIgE provided lower PPVs in South African peanut-sensitized patients; the optimal cutoffs to diagnose PA in this population were ≥15 kU/L for peanut sIgE and ≥8 kU/L for Ara h 2 sIgE, which had 80% and 93% PPV, respectively.

Concomitant atopic diseases can also modulate the clinical relevance of a given allergy test result. Patients with atopic eczema tend to have a polyclonal IgE response to allergens that often lacks clinical expression. This underscores the importance of a judicious selection of allergens to be tested. Grabenhenrich et al showed that for a given component-sIgE level, a high total IgE (>500 kU/L) significantly reduced the probability of clinical peanut or hazelnut allergy, respectively, particularly at low levels of Ara h 2 sIgE or Cor a 14 sIgE. In patients with birch or grass pollen allergy, high levels of sIgE to plant foods, such as peanut or hazelnut, may have a low probability of a systemic allergic reaction. These are the cases where determining sIgE to individual allergens that are involved in cross-reactivity (eg, Ara h 8 and Cor a 1) can be helpful in distinguishing real FA from sensitization secondary to pollen allergy, which can cause PFAS but usually not systemic allergic reactions.
occurs more frequently because of the increased use of anticipatory testing and has important resource implications.102

Many factors affect the decision as to whether to perform an OFC (Table VI). The most important considerations are provided by the clinical history; the previous reaction history and recent exposure to the food in question may avert the need (already consuming) or lead to deferment (recent reaction, poorly controlled asthma) of an OFC. SPT and sIgE testing will also affect this decision; in a patient being assessed for the initial diagnosis of FA, a recent convincing history of an allergic reaction to an identified food, concomitant SPT ≥ 3 mm and/or sIgE to the whole allergen ≥0.35 kU/L may be sufficient to confirm the diagnosis without the need for further testing or an OFC. In cases where the history and SPT/sIgE testing do not provide a clear answer, further testing with sIgE to components or the BAT may be warranted, before deciding to perform an OFC.

When monitoring a patient for resolution of FA, it is generally recommended that children with a 50% chance of experiencing a negative challenge be good candidates for an OFC.103 A predictive 50% negative cutoff of 2 kU/L has been identified for the resolution of egg and cow’s milk allergies.104 The rate of decline of IgE to cow’s milk and egg has also been shown to predict resolution; a 50% decrease in respective sIgE over 12 months is associated with a 52% probability of tolerance to egg and 31% probability of tolerance to cow’s milk.105 Baseline sIgE and SPT wheal size and severity of eczema also affect the rate of resolution and this has been incorporated into a practical computerized algorithm by Wood et al106 for CMA. In the case of peanut, sIgE ≤2 kU/L and ≤5 kU/L have been shown to give a 50% prediction of a negative peanut challenge in children with and without a history of peanut reaction, respectively.107 A systematic review by Peters et al108 in 2013 provides further details on sIgE and SPT cutoffs to predict the resolution of cow’s milk, egg, and peanut allergies.

When considering performing an OFC it is vital that the patient or parents of the child undergoing the OFC understand the rationale for this and the importance of introducing the food into the diet after a negative challenge. Several studies have shown that 18% to 32% of patients do not introduce the food after passing an OFC.109-111 This is of concern as the recurrence of FA (particularly peanut) has been shown to occur if the food continues to be avoided after the OFC or is consumed in very small quantities.112-114 This would suggest that the immune system needs ongoing exposure to maintain tolerance; however, this conflicts with the fact that children develop tolerance whilst avoiding a food. Nonetheless, if the food is not important to the patients and they are not planning to introduce it, then it may be better not to proceed with the OFC. Dietetic advice to prepare recipes that the child will accept and suggestions for foods for mixing can avert failed OFCs; dietitians can also advise on ways to introduce the food. Another important consideration is to avert failed OFCs due to the patient or family not being prepared for the OFC due to uncontrolled asthma, continued antihistamine use, and inability or refusal to complete the OFC. Clear verbal and written information before the OFC is therefore essential.115

Severity

Identifying patients at high risk of a severe reaction to foods is important for the management of patients diagnosed with FA. Previous studies have shown contradictory results about the utility of food-specific IgE levels in assessing severity of FA.8,115,116 sIgE to certain allergen components, such as Ara h 2 in peanut, has been associated with more severe reactions than sIgE to whole peanut or other single allergens, which is corroborated by in vitro studies of basophil activation and mediator release assays where Ara h 2 and Ara h 6 have been shown to be the most potent elicitors of effector cell response.25 On the contrary, sIgE to Ara h 8 is associated with PFAS. Higher reactivity on the BAT to food allergens has been shown to be associated with greater severity of allergic reactions during an OFC.117-119 In a peptide microarray, a broader IgE epitope diversity is associated with more severe reactions and with a greater degree of basophil activation and degranulation after allergen stimulation.20,121

The above data need to be applied with caution to the assessment of individual patients. For example, patients with raised Ara h 2 sIgE do not necessarily have severe PA and can actually pass a peanut OFC;122 10% of patients with PFAS can have systemic reactions and 1% to 2% experience anaphylaxis.123-124 The risk assessment of allergic patients depends on factors other than mere individual players of IgE-mediated food-induced allergic reactions (such as single allergens or epitopes, IgE, or basophils) and requires a holistic clinical evaluation of the patient.

CONCLUSIONS

In vitro allergy tests are useful in diagnosing IgE-mediated FA and support the decision of whether an OFC is necessary to reach an accurate diagnosis. Validated cutoffs are reliable when applied to a similar patient population to the one where they were developed. Patient-specific factors can modulate the probability of clinical allergy of a given sIgE result. IgE to allergen components can provide more precise information about IgE specificity. The BAT assesses the function of IgE in its ability to mediate allergen-induced effector cell activation. Further research is needed to improve our understanding about how the information of various tests can be combined for optimal diagnostic accuracy to reduce the need to perform OFCs to a minimum.

REFERENCES

1. Johansson SG, Hourihane JO, Bousoquet J, Brujinzeel-Koomen C, Dreborg S, Haahlet T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813-24.
2. Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010;126:1105-18.
3. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010;125:S73-80.
4. Wang J, Godbold JH, Sampson HA. Correlation of serum allergy (IgE) tests performed by different assay systems. J Allergy Clin Immunol 2008;121:1219-24.
5. Bazata M, Hamburger RN. Standardization and stability of immunoglobulin E (IgE). J Allergy Clin Immunol 1972;49:189-91.
6. Bernard H, Patey E, Mondoulet L, Burks AW, Bannon GA, Wal JM, et al. Serological characteristics of peanut allergy in children. Allergy 2003;58:1285-92.
7. Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. J Allergy Clin Immunol 2005;115:1291-6.
8. Wainstein BK, Studdert J, Ziegler M, Ziegler JB. Prediction of anaphylaxis during peanut food challenge: usefulness of the peanut skin prick test (SPT) and specific IgE level. Pediatr Allergy Immunol 2010;21:603-11.
9. Johanssen H, Nolan R, Pascoe EM, Cuthbert P, Noble V, Corderoy T, et al. Skin prick testing and peanut-specific IgE can predict peanut challenge
outcomes in preschool children with peanut sensitization. Clin Exp Allergy 2011;41:994-1000.

10. DumnGalvin A, Daly D, Cullinan C, Stonke E, Keeton D, Erlewyn-Lajeunesse M, et al. Highly accurate prediction of food challenge outcome using routinely available clinical data. J Allergy Clin Immunol 2011;127:633-9.

11. Glaumann S, Nopp A, Johansson SG, Rudengren M, Borres MP, Nilsson C. Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children. Allergy 2012;67:242-7.

12. Ebisawa M, Moverare R, Sato S, Maryama N, Borres MP, Komata T. Measurement of Ara h 1, 2, and 3-specific IgE antibodies is useful in diagnosis of peanut allergy in Japanese children. Pediatr Allergy Immunol 2012;23:573-81.

13. Klemans RJ, van Os-Medendorp H, Blankestijn M, Bruitjneel-Koomen CA, Knol EF, Knulst AC. Diagnostic accuracy of specific IgG to components in diagnosing peanut allergy: a systematic review. Clin Exp Allergy 2015;45:720-30.

14. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001;107:891-6.

15. Roberts G, Lack G. Food allergy—getting more out of your skin prick tests. Clin Exp Allergy 2000;30:1495-8.

16. Santos AF, Douiri A, Becares N, Wu SY, Stephens A, Rudulovic S, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J Allergy Clin Immunol 2014;134:645-52.

17. van Nieuwlaat NH, Lasfar W, Meijer Y, Kentie PA, Flinterman AE, Pasmans SG, et al. Utility of peanut-specific IgE levels in predicting the outcome of double-blind, placebo-controlled food challenges. J Allergy Clin Immunol 2010;125:1391-2.

18. Peters RL, Allen KJ, Dharmage SC, Tang ML, Koplin JJ, Ponsonby AL, et al. Skin prick test responses and allergen-specific IgE levels as predictors of peanut, egg, and sesame allergy in infants. J Allergy Clin Immunol 2013;132:874-80.

19. Rance F, Abbal M, Lauwers-Cances V. Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays. J Allergy Clin Immunol 2002;109:1027-33.

20. Santos AF, Lack G. Basophil activation test: food challenge in a test tube or specialist research tool? Clin Transl Allergy 2016;6:10.

21. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527.

22. Patelis A, Borres MP, Kober A, Berthold M. Multiplex component-based allergen microarray in recent clinical studies. Clin Exp Allergy 2016;46:390.

23. Heaps A, Carter S, Selwood C, Moody M, Unsworth J, Deacock S, et al. The utility of casein-specific IgE and IgG4 antibodies in cow’s milk allergy. Clin Mol Allergy 2012;10:1.

24. Pasmans SG, et al. Utility of casein-specific IgE levels in predicting the outcome of clinical reactivity in the follow-up of the cow’s milk allergens. Clin Exp Allergy 2004;34:866-70.

25. Alcocer M, Rundqvist L, Larsson G. Ber e 1 protein: the versatile major allergen predominantly Ara h2 and Ara h6, which remains stable over time. Clin Exp Allergy 2004;34:583-90.

26. Flinterman AE, Van Hoffen E, Van der Heijden C, Van Gestel P, De Graag M, Van Der Heijden C, et al. Measurement of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by folded and functional recombinant protein. Peptides 2009;30:1213-21.

27. De Knop SJ, Verweij MM, Grimmelikhuijzen M, Philips E, Hagedoorns MM, Brilts DJ, et al. Age-related sensitization profiles for hazelnut (Corylus avellana) in a birch-endemic region. Pediatr Allergy Immunol 2011;22:e39-49.

28. Søder C, Culerrier R, Granier C, Ranoe C, Dider A, Barre A, et al. Expression of IgG1, IgG2, IgG4 and IgE antibody responses to peanut allergens in a selected sample of peanut allergic children. Allergy 2012;67:326-31.

29. Alcocer M, Rundqvist L, Larsson G. Ber e 1 protein: the versatile major allergen predominantly Ara h2 and Ara h6, which remains stable over time. Clin Exp Allergy 2004;34:583-90.

30. Ebisawa M, Mitsui A, Komata T, Borres MP, Komata T. Measurement of Ara h1, 2, and 3-specific IgE antibodies is useful in diagnosis of peanut allergy in Japanese children. Pediatr Allergy Immunol 2012;23:573-81.

31. Takeda JD, Sicheler SH, Sampson HA. Clinical reactivity to hazelnut may be better identified by component testing than traditional testing methods. J Allergy Clin Immunol Pract 2014;2:633-4.
54. Beyer K, Chung D, Schulz G, Mishoe M, Niggemann B, Wahn U, et al. The role of wheat omega-5 gliadin IgE antibodies as a diagnostic tool for wheat allergy in childhood. J Allergy Clin Immunol 2008;122:419-21.

55. Holzhauser T, Wackermann O, Ballermann-Weber BK, Bindels-Jenssen C, Schubla J, Permon-Gandorova V. Soybean (Glycine max) allergy in Europe: Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential diagnostic markers for severe allergic reactions to soy. J Allergy Clin Immunol 2009;123:452-8.

56. Klemans RA, Otte D, Knol M, Knol EF, Meijer Y, Gmelig-Meyling FH, et al. The diagnostic value of specific IgE to Ara h 2 to predict peanut allergy in children is comparable to a validated and updated diagnostic prediction model. J Allergy Clin Immunol Pract 2013;1:157-63.

57. Ebisawa M, Brostedt P, Sjölander S, Sato S, Borres MP, Ito K. Gly m 2S albumin is a major allergen with a high diagnostic value in soybean-allergic children. J Allergy Clin Immunol 2013;132:976-8.

58. Kattan JD, Sampson HA. Clinical reactivity to soy is best identified by component testing to Gly m 8. J Allergy Clin Immunol Pract 2015;3:970-2.

59. Kleine-Tebbe J, Vogel L, Crowell DN, Haustein UF, Vieths S. Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1-related PR-10 protein in soybean. SAM22. J Allergy Clin Immunol 2002;110:797-804.

60. Gupta RS, Lau CH, Hamilton RG, Donnell A, Newhall KK. Predicting outcomes of oral food challenges by using the allergen-specific IgE-total IgE ratio. J Allergy Clin Immunol Pract 2014;2:300-5.

61. Mehl A, Verstege A, Staden U, Kulig M, Nocon M, Beyer K, et al. Utility of the ratio of food-specific IgE/total IgE in predicting symptomatic food allergy in children. Allergy 2005;60:1034-9.

62. Grabenhinrich L, Lange L, Hartl M, Kalb B, Ziegert M, Finger A, et al. The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses. J Allergy Clin Immunol 2016;137:1751-60.

63. Santos AF, James LK, Bahnson HT, Shamji MH, Couto-Francisco NC, Islam S, et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 2016;135:1249-56.

64. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015;372:803-13.

65. Caubet JC, Bencharitiwong R, Moshier E, Godbold JH, Sampson HA, Nowak-Wegrzyn A, et al. Basophil allergen threshold sensitivity and component-resolved diagnosis of peanut allergy: sensitivity and specificity. Clin Exp Allergy 2008;38:1299-305.

66. Wegrzyn A. Sensitivity and specificity of ovomucoid- and ovalbumin-specific IgE to challenge milk, egg, and soy in children. Allergy 2007;62:408-14.

67. Stevens WJ. Flow cytometric analysis of in vitro activated basophils, specificity and sensitivity of IgE-mediated food allergy. Pediatr Allergy Immunol 1997;100:444-51.

68. Bruijnzeel-Koomen CA, Knol EF, et al. T cell responses to major peanut allergens. J Allergy Clin Immunol 2010;125:Suppl 1:54-61.

69. Lakatos P, Tordai A, Balogh Z, Denes P, Szalai I, et al. Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy. J Allergy Clin Immunol 2010;125:695-702.

70. Sampson HA, Ho DG. Relationship between food-specific IgE and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 2007;120:1218-24.

71. Fagan TJ. Letter: nomogram for Bayes theorem. N Engl J Med 1975;293:257.

72. Fehr WG, Lin J, Bardina L, Goldis M, Nowak-Wegrzyn A, Shreffler WG, et al. Performance of different in vitro techniques in the molecular diagnosis of peanut allergy. J Allergy Clin Immunol 2008;122:589-94.

73. Santos AF, James LK, Bahnson HT, Shamji MH, Couto-Francisco NC, Islam S, et al. Total IgE/IgG(4) ratios in milk allergy. J Allergy Clin Immunol 2012;129:739-47.

74. Christiansen LH, Holm J, Lund G, Riise E, Lund K. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol 2008;122:298-304.

75. Ocmant A, Mulier S, Hanssens L, Goldman M, Casimir G, Mascart F, et al. Correlation of IgE/IgG anti-albumin is a major allergen with a high diagnostic value in soybean-allergic children. Allergy 2009;39:1234-51.

76. Flinterman AE, Pasmans SG, den Hartog Jager CF, Hoekstra MO, Scheurer S, et al. Performance of different in vitro techniques in the molecular diagnosis of peanut allergy. J Allergy Clin Immunol Pract 2014;2:300-5.

77. Wolbink F, Kunz J, Kempf WE, Grimmler C, Fischer J, Biedermann T. The clinical relevance of birch pollinosis profilin cross-reactivity in sensitized patients [e-pub ahead of print]. Allergy 2016. http://dx.doi.org/10.1111/all.13040.

78. Ocmant A, Mulier S, Hanssens L, Goldman M, Casimir G, Mascart F, et al. Correlation of IgE/IgG anti-albumin is a major allergen with a high diagnostic value in soybean-allergic children. Allergy 2009;62:408-14.

79. Glaumann S, Nilsson C, Johansson SG, Asarnoj A, Wickman M, Borres MP, et al. Evaluation of basophil allergen threshold sensitivity (CD-sens) to peanut and Ara h 8 in children IgE-sensitized to Ara h 8. Clin Mol Allergy 2015;13:5.
99. Vereda A, van Hage M, Ahlstedt S, Ibanez-Herranz J, van Osdijk J, et al. Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions. J Allergy Clin Immunol 2011;127:603-7.

100. McGowan EC, Peng RD, Salo PM, Zeldin DC, Kett CA. Changes in food-specific IgE over time in the National Health and Nutrition Examination Survey (NHANES). J Allergy Clin Immunol Pract 2016;4:713-20.

101. Sicherer SH, Wood RA, Stabilein D, Burks AW, Liu AH, Jones SM, et al. Immunologic features of infants with milk or egg allergy enrolled in an observational study (Comsortium Food Allergy Research) of food allergy. J Allergy Clin Immunol 2010;125:1077-83.

102. Anagnostou K, Stiefel G, Brough H, du Toit G, Lack G, Fox AT. Active management of food allergy: an emerging concept. Arch Dis Child 2015;100:386-90.

103. Nowak-Wegrzyn A, Assa’ad AH, Bahna SL, Bock SA, Sicherer SH, Teuber SS, et al. Work Group report: oral food challenge testing. J Allergy Clin Immunol 2009;123:S365-83.

104. Perry TT, Matsui EC, Kay Conover-Walker M, Wood RA. The relationship of allergen-specific IgE levels and oral food challenge outcome. J Allergy Clin Immunol 2004;114:144-9.

105. Shek LP, Soderstrom L, Ahlstedt S, Beyer K, Sampson HA. Determination of no-observed-adverse-effect levels and eliciting doses in food allergy. J ALLERGY CLIN IMMUNOL PRACT MARCH/APRIL 2017

106. Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol 2013;131:805-12.

107. Sicherer SH, Morrow EH, Sampson HA. Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol 2000;105:582-6.

108. Peters RL, Gurrin LC, Dharmage SC, Koplin J, Allen KJ. The natural history of IgE-mediated food allergy: can skin prick tests and serum-specific IgE predict the resolution of food allergy? Int J Environ Res Public Health 2013;10:5039-61.

109. Eigenmann PA, Caubet JC, Zamora SA. Continuing food-avoidance diets after negative food challenges. Pediatr Allergy Immunol 2006;17:601-5.

110. van Erp FC, Boot J, Knulst AC, Pasmans SG, van der Ent CK, Groot Kleine Wijnands JD, et al. Determination of no-observed-adverse-effect levels and eliciting doses in a representative group of peanut-sensitized children. J Allergy Clin Immunol 2006;117:448-54.

111. Hourihane JO, Grimshaw KE, Lewis SA, Briggs RA, Trewin JB, King RM, et al. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community? Clin Exp Allergy 2005;35:1227-33.

112. Rubas A, Vivinus-Nobot M, Bourrier T, Saggio B, Albertini M, Bernard A. Beneﬁt of the basophil activation test in deciding when to reintroduce cow’s milk in allergic children. Allergy 2011;66:92-100.

113. Santos AF, Du Toit G, Douris A, Radulovic S, Stephens A, Turcanu V, et al. Distinct parameters of the basophil activation test reﬂect the severity and threshold of allergic reactions to peanut. J Allergy Clin Immunol 2015;135:179-86.

114. Song Y, Wang J, Leung N, Wang LX, Lisann L, Sicherer SH, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol 2012;129:1056-63.

115. Turner PJ, Dawson TC, Skypala II, Fox AT. Management of pollen food and oral allergy syndrome by health care professionals in the United Kingdom. Allergy Asthma Immunol Res 2015;7:293-302.

116. Busse PJ, Nowak-Wegrzyn AH, Noone SA, Sampson HA, Sicherer SH. Recurrent peanut allergy. N Engl J Med 2002;347:1535-6.

117. Flinterman AE, Knulst AC, Meijer Y, Bruijnzeel-Koomen CA, Pasmans SG. Acute allergic reactions in children with AEDS after prolonged cow’s milk elimination diets. Allergy 2006;61:370-4.

118. Flinterman AE, Knulst AC, Meijer Y, Bruijnzeel-Koomen CA, Pasmans SG. Ova lbumin-speciﬁc IgE/IgG4 ratio might improve the prediction of cooked and uncooked egg tolerance development in egg-allergic children. Clin Exp Allergy 2014;44:579-88.

119. Flinterman AE, Knulst AC, Meijer Y, Bruijnzeel-Koomen CA, Pasmans SG. Ovalbumin-speciﬁc IgE/IgG4 ratio might improve the prediction of cooked and uncooked egg tolerance development in egg-allergic children. Clin Exp Allergy 2014;44:579-88.

120. Mansoor DK, Sharma HP. Clinical presentations of food allergy. Pediatr Clin North Am 2011;58:315-26.

121. Flinterman AE, Knulst AC, Meijer Y, Bruijnzeel-Koomen CA, Pasmans SG. Ovalbumin-speciﬁc IgE/IgG4 ratio might improve the prediction of cooked and uncooked egg tolerance development in egg-allergic children. Clin Exp Allergy 2014;44:579-88.

122. Hautojärvi R, Hautojärvi J, Himmälä I, Haahtela T, Pihlajameri K, Myllylä M. Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. J Allergy Clin Immunol 2008;121:737-43.

123. Dang TD, Tang M, Choo S, Licciardi PV, Koplin JJ, Martin PE, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol 2012;129:1056-63.

124. Turner PJ, Dawson TC, Skypala II, Fox AT. Management of pollen food and oral allergy syndrome by health care professionals in the United Kingdom. Allergy Asthma Immunol Res 2015;7:293-302.

125. Blankestijn MA, Blom M, Otten HG, Baanert JL, Taylor SL, Bruijnzeel-Koomen CA, et al. Specific IgE to Jug r 1 has no additional value compared to extract based testing in diagnosing walnut allergy in adults. J Allergy Clin Immunol 2017;139:688-90.e4.

126. Vazquez-Ortiz M, Pascal M, Jimenez-Fejoo R, Lozano J, Giner MT, Alsina L, et al. Ovalbumin-specific IgE/IgG4 ratio might improve the prediction of cooked and uncooked egg tolerance development in egg-allergic children. Allergy Asthma Immunol Res 2014;44:579-88.

127. Hamada Y, Kando N, Yatsu M, Kobayashi T, Maeda T, Hino A, et al. Ovo mucoids IgE is a better marker than egg white-specific IgE to diagnose boiled egg allergy. J Allergy Clin Immunol 2012;129:1681-2.

128. Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S, Nowak-Wegrzyn A. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 2008;122:977-83.